Efficacity and Safety of the Fluocinolone Acetonide Implant in Uveitic Macular Edema: A Real-Life Study from the French Uveitis Network

Efficacity and Safety of the Fluocinolone Acetonide Implant in Uveitic Macular Edema: A Real-Life Study from the French Uveitis Network

Purpose: To evaluate the safety and efficacy of the fluocinolone acetonide implant (FAi, Iluvien<sup>®</sup> Horus pharma, Nice, France) in non-infectious uveitic macular edema (UME) and to approach the predictive factors of treatment response. Methods: This retrospective, multicenter re...

Full description

Bibliographic Details
Main Authors:	Matthieu Jabbour, Laurent Kodjikian, Alexandre Bourdin, Marie-Bénédicte Rougier, Yasmine Serrar, Michel Weber, Hélène Massé, Driss Mazhar, Sara Perez-Roustit, Christophe Chiquet, Marie Nöelle Delyfer, Bahram Bodaghi, Sara Touhami
Format:	Article
Language:	English
Published:	MDPI AG 2024-02-01
Series:	Journal of Personalized Medicine
Subjects:	uveitic macular edema dexamethasone fluocinolone acetonide implant chronic non-infectious uveitis predictive factor DRIL
Online Access:	https://www.mdpi.com/2075-4426/14/3/245

Similar Items

Intravitreal 0.19 mg Fluocinolone Acetonide Implant in Non-Infectious Uveitis
by: Muaas Hikal, et al.
Published: (2021-09-01)

Real-World Efficacy and Safety of Fluocinolone Acetonide Implant for Diabetic Macular Edema: A Systematic Review
by: Laurent Kodjikian, et al.
Published: (2021-01-01)

Ahmed glaucoma valve in uveitic patients with fluocinolone acetonide implant-induced glaucoma: 3-year follow-up
by: Kubaisi B, et al.
Published: (2018-05-01)

Migration of a fluocinolone acetonide implant (Yutiq) to the anterior chamber and its nonurgent removal
by: Hamidah Mahmud, et al.
Published: (2020-12-01)

Biomarkers to Predict the Success of Treatment with the Intravitreal 0.19 mg Fluocinolone Acetonide Implant in Uveitic Macular Edema
by: Lucy Joanne Kessler, et al.
Published: (2022-03-01)

Management of Patients with Diabetic Macular Edema Switched from Dexamethasone Intravitreal Implant to Fluocinolone Acetonide Intravitreal Implant
by: Stéphanie Baillif, et al.
Published: (2022-11-01)

Iluvien™ (Fluocinolone Acetonide 0.19 mg Intravitreal Implant) in the Treatment of Diabetic Macular Edema: A Review
by: William Fusi-Rubiano, et al.
Published: (2018-09-01)

Scleral fixation of fluocinolone acetonide implant
by: Homayoun Tabandeh, et al.
Published: (2020-09-01)

Achieving Quiescence with Fluocinolone Implants
by: Freia McGregor, et al.
Published: (2021-05-01)

Long-Acting Fluocinolone Acetonide Intravitreal Implant for Recurrent Bilateral Non-Infectious Posterior Uveitis
by: Babel AT, et al.
Published: (2022-11-01)

Characterization of Transcriptomic and Proteomic Changes in the Skin after Chronic Fluocinolone Acetonide Treatment
by: Yongsu Choi, et al.
Published: (2022-12-01)

Preserflo Microshunt Surgery for Ocular Hypertension following Intravitreal Fluocinolone Acetonide Implant Removal: A Case Report
by: Amina Rezkallah, et al.
Published: (2022-12-01)

Clinical utility of intravitreal fluocinolone acetonide (Iluvien®) implant in the management of patients with chronic diabetic macular edema: a review of the current literature
by: Saedon H, et al.
Published: (2017-03-01)

Intravitreal methotrexate and fluocinolone acetonide implantation for Vogt-Koyanagi-Harada uveitis
by: Jong G. Park, et al.
Published: (2020-09-01)

Sustained Control from Recurring Non-Infectious Uveitic Macular Edema with 0.19 mg Fluocinolone Acetonide Intravitreal Implant – A Case Report
by: Jorge Meira, et al.
Published: (2019-09-01)

Investigation of Solvolysis Kinetics of New Synthesized Fluocinolone Acetonide C-21 Esters—An In Vitro Model for Prodrug Activation
by: Katarina D. Karljikovic-Rajic, et al.
Published: (2011-03-01)

Treatment of refractory diabetic macular edema with a fluocinolone acetonide implant in vitrectomized and non-vitrectomized eyes
by: Alberto La Mantia, et al.
Published: (2018-12-01)

Biocompatible lipid nanocarriers for improved skin delivery of fluocinolone acetonide: Physicochemical and in vitro performances
by: Stanković Tijana, et al.
Published: (2023-01-01)

Efficacy and Safety of Intravitreal Fluocinolone Acetonide Implant for Chronic Diabetic Macular Edema Previously Treated in Real-Life Practice: The REALFAc Study
by: Thibaud Mathis, et al.
Published: (2022-03-01)

Fluocinolone Acetonide Implant Injected 1 Month after Dexamethasone Implant for Diabetic Macular Oedema: the ILUVI1MOIS Study
by: Nicolas Rousseau, et al.
Published: (2023-06-01)

Intravitreal Fluocinolone Acetonide 0.19 mg Implant in a Patient with Resistant Blau Syndrome: A Case Report
by: Khushi Saigal, et al.
Published: (2024-01-01)

Classical versus chemometrics tools for spectrophotometric determination of fluocinolone acetonide, ciprofloxacin HCl and ciprofloxacin impurity-A in their ternary mixture
by: Mahmoud A. Tantawy, et al.
Published: (2023-06-01)

Treating Diabetic Macular Oedema (DMO): real world UK clinical outcomes for the 0.19mg Fluocinolone Acetonide intravitreal implant (Iluvien™) at 2 years
by: William Fusi-Rubiano, et al.
Published: (2018-02-01)

Clinical Effectiveness of Intravitreal Fluocinolone Acetonide (FAc) (ILUVIEN™) in Patients with Diabetic Macular Oedema (DMO) Refractory to Prior Therapy: The Manchester Experience
by: James F. Young, et al.
Published: (2019-07-01)

In Vitro and Ex Vivo Evaluation of Fluocinolone Acetonide–Acitretin-Coloaded Nanostructured Lipid Carriers for Topical Treatment of Psoriasis
by: Hassan Raza, et al.
Published: (2022-11-01)

Rapid Structural and Functional Improvements with the 0.19 mg Fluocinolone Acetonide Intravitreal Implant for Patients with DME and Low Visual Acuity: 6-Month Data from the UAE
by: Elbarky AM
Published: (2020-03-01)

Visual function and retinal morphological changes after single suprachoroidal delivery of fluocinolone acetonide (Iluvien®) implant in eyes with chronic diabetic macular edema
by: Ehab N. El Rayes, et al.
Published: (2023-03-01)

Efficacy and safety of sustained-delivery fluocinolone acetonide intravitreal implant in patients with chronic diabetic macular edema insufficiently responsive to available therapies: a real-life study
by: Massin P, et al.
Published: (2016-07-01)

Risk factors for failing sub-Tenon’s triamcinolone acetonide for uveitic macular edema
by: Amit K. Reddy, et al.
Published: (2024-02-01)

Intravitreal Fluocinolone Acetonide for Diabetic Macular Edema: Long-Term Effect and Structure/Function Correlation
by: Angelo Maria Minnella, et al.
Published: (2022-10-01)

The USER Study: A Chart Review of Patients Receiving a 0.2 µg/day Fluocinolone Acetonide Implant for Diabetic Macular Edema
by: Alexander Eaton, et al.
Published: (2018-12-01)

A Review of the Effectiveness and Side-Effects of Fluocinolone Acetonide 0.1% in the Treatment of Oral Mucosal Diseases
by: Kobkan Thongprasom
Published: (2017-01-01)

Real-world retrospective comparison of 0.19 mg fluocinolone acetonide and 0.7 mg dexamethasone intravitreal implants for the treatment of diabetic macular edema in vitrectomized eyes
by: Coelho J, et al.
Published: (2019-09-01)

Challenging Clinical Cases – A Walk Through Supplemental Therapy with Intravitreal Ranibizumab Therapy Following Treatment of Diabetic Macular Edema with the 0.19 mg Fluocinolone Acetonide Implant (ILUVIEN®)
by: Pessoa B, et al.
Published: (2020-09-01)

Cost-effectiveness of fluocinolone acetonide implant (ILUVIEN®) in UK patients with chronic diabetic macular oedema considered insufficiently responsive to available therapies
by: Michal Pochopien, et al.
Published: (2019-01-01)

Intraocular Pressure Changes Are Predictive of Ocular Hypertension Onset After Fluocinolone Acetonide Implant: Significant Cutoffs and the Role of Previous DEX Implant
by: Alessandro Arrigo, et al.
Published: (2021-08-01)

Early adoption of the fluocinolone acetonide (FAc) intravitreal implant in patients with persistent or recurrent diabetic macular edema (DME)
by: McCluskey JD, et al.
Published: (2019-04-01)

Intravitreal therapeutic agents in noninfectious uveitic macular edema
by: Kunal Kaushik Shah, et al.
Published: (2018-01-01)

Effectiveness of 190 μg Fluocinolone Acetonide and 700 μg Dexamethasone Intravitreal Implants in Diabetic Macular Edema Using the Area-Under-the-Curve Method: The CONSTANT Analysis
by: Zarranz-Ventura J, et al.
Published: (2020-06-01)

Comment on ’Effectiveness of 190 μg Fluocinolone Acetonide versus 700 μg Dexamethasone Intravitreal Implants in Diabetic Macular Edema Using the Area-Under-the-Curve Method: The CONSTANT Analysis’ [Response to Letter]
by: Zarranz-Ventura J, et al.
Published: (2020-11-01)